廣告

2021年6月28日 星期一

地球,人間煉獄 CLIV (154th、154期) :Delta Variant Drives New Lockdowns in Asia and Australia. 新冠变种病毒株Delta传染力强,距离全美大爆发仅有一个月时间;WHO Urges Vaccinated People to Wear Masks; CDC Still Says No Need. Scientists developing a single shot to protect against coronaviruses past, present and future. Oxford/Pfizer 混打,仍有效

 地球,人間煉獄 CLIV (154th、154期) : 

The World Health Organization is urging people—even if they are fully vaccinated against COVID—to continue wearing a mask, in contrast with guidance from the U.S. Centers for Disease Control and Prevention.



美国传染病专家预言,新冠变种病毒株Delta传染力强,距离全美大爆发仅有一个月时间;拜登总统警告说,这个变种病毒将导致更多美国人死亡。




上个月在台湾突然暴增的新冠疫情持续趋缓,星期一(6月28日)台湾本土新增60例确诊病例,这是新一波疫情爆发、实施第三级警戒以来的单日新低;染疫死亡个案3例,新冠疫情爆发以来染疫死亡人数累计达635人。

Scientists have set out to ease fears of another pandemic by developing a single shot to protect against coronaviruses past, present and future.

The AstraZeneca Covid-19 vaccine provides a strong bump to immunity when given as a third dose, or booster, more than six months after the second shot, according to a study.
Third AstraZeneca Covid Shot Can Be Effective Booster, Study Shows
WSJ.COM
Third AstraZeneca Covid Shot Can Be Effective Booster, Study Shows
Preliminary Oxford research also found that the two-shot reg
NEW OXFORD-LED STUDY: Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19.
The study has found:
• Mixed schedules involving Pfizer-BioNTech and Oxford-AstraZeneca generate strong immune response against SARS-CoV2 spike IgG protein.
• Doses administered four weeks apart; data for 12-week dose interval due soon.
• Immune responses differed according to order of immunisation, with Oxford-AstraZeneca followed by Pfizer-BioNTech generating the better immune response out of the two mixed schedules.
This means all possible vaccination schedules involving the Oxford-AstraZeneca and Pfizer-BioNTech vaccines could potentially be used against COVID-19.
Professor Matthew Snape, Associate Professor in Paediatrics and Vaccinology at the University of Oxford, and Chief Investigator on the trial, said: ‘The Com-COV study has evaluated “mix and match” combinations of the Oxford and Pfizer vaccines to see to what extent these vaccines can be used interchangeably, potentially allowing flexibility in the UK and global vaccine roll-out.
‘The results show that when given at a four-week interval both mixed schedules induce an immune response that is above the threshold set by the standard schedule of the Oxford/AstraZeneca vaccine. The investigators would like to thank the participants that made this important study possible.’


沒有留言:

網誌存檔